Cumberland Pharmaceuticals (CPIX) Other Non-Current Liabilities (2010 - 2026)

Cumberland Pharmaceuticals has disclosed Other Non-Current Liabilities across 17 years of filings, most recently posting $5.6 million for Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $5.6 million, down 6.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.6 million (down 6.44% YoY), and the FY2025 annual result was $5.8 million, down 7.58% from the prior year.
• Other Non-Current Liabilities came in at $5.6 million for Q1 2026 at Cumberland Pharmaceuticals, down from $5.8 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $11.3 million in Q1 2022 to a low of $5.6 million in Q1 2026.
• The 5-year median for Other Non-Current Liabilities is $6.5 million (2023), against an average of $7.1 million.
• Across the five-year window, Other Non-Current Liabilities jumped 44.56% in 2022 and plunged 37.38% in 2023, its largest moves.
• Cumberland Pharmaceuticals' Other Non-Current Liabilities stood at $7.6 million in 2022, then dropped by 14.92% to $6.5 million in 2023, then slipped by 2.38% to $6.3 million in 2024, then declined by 7.58% to $5.8 million in 2025, then fell by 3.48% to $5.6 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $5.6 million (Q1 2026), $5.8 million (Q4 2025), and $6.0 million (Q3 2025), per Business Quant data.